Sun Pharma Advanced Research Company Limited (SPARC) — Board Meeting | 10 August 2026 (2 announcements)

SPARC held its 21st AGM on August 10, 2026, via video conference, where shareholders approved all resolutions including the appointment of Anil Kumar Raghavan as Managing Director and CEO, and the retirement of Dr. Rajamannar Thennati without re-election. Chairman Dilip Shanghvi presented the annual report highlighting financial discipline, pipeline progress like monetization of a USFDA Paediatric Rare Disease Voucher for $195 million, and strategic focus on oncology and immunology. The meeting concluded at 5:53 PM after voting on ordinary and special business items.

The board approved unaudited standalone and consolidated financial results for Q1 FY26 ending June 30, 2026, along with promoter reclassification requests and warrant allotment to Shanghvi Finance. The unaudited standalone revenue reached ₹3,992 lakhs with a net loss of ₹2,098 lakhs before tax, while consolidated revenue was ₹6,358 lakhs and net loss of ₹2,078 lakhs. The board also approved reclassification of promoter group members to public status subject to regulatory approvals.